FURLONG Archives - Medical Conferences

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April 2022 10:43

site created by:

HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com